Yuping Li

Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial

J. Smith, F. Martinez, I. Noth, 2021, Pulmonary Therapy.

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.

S. Birring, J. Smith, A. Morice, 2020, The Lancet. Respiratory medicine.

Gefapixant in two randomised dose-escalation studies in chronic cough

J. Smith, A. Ford, Steven A. Smith, 2020, European Respiratory Journal.

The role of tolvaptan in pulmonary hypertension: A retrospective study

Yuping Li, Qiaoli Chen, H. Luo, 2022, Medicine.